Skip to main content

Advertisement

Log in

Early Progressing Follicular Lymphoma

  • Lymphomas (T Hilal, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Follicular lymphoma is an indolent lymphoma which does not limit life expectancy in most patients; however, approximately 20% of patients will experience progression of disease within 24 months (POD24) of diagnosis and have inferior survival outcomes. To date, no clinical, genetic, or tumor microenvironment prediction models have been able to definitively predict which patients will experience POD24 which limits the ability to alter frontline management of patients suspected to be at high risk of early progression. Here, we review recent literature regarding novel prediction models and management recommendations for POD24 patients.

Recent Findings

Recent studies have revealed novel clinicopathologic prediction models which may be closer to identifying patients at risk of POD24. In addition, several clinical trials utilizing novel therapies such as tazemetostat, obinutuzumab, PI3K inhibitors, and lenalidomide have been performed which help further guide treatment. Ongoing trials seek to identify the optimal management of these patients, and data from bispecific antibodies and CAR T cell therapies is forthcoming.

Summary

With ongoing research efforts, hope remains that we are closer to being able to predict which patients will experience early progressing follicular lymphoma and have an improved management plan for those who do in order to improve survival outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

Data Availability

Data sharing is not applicable to this article as no datasets were generated or analyzed for this review.

Code Availability

Not applicable.

References

  1. National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database: NPCR and SEER Incidence. In: United States Department of Health and Human Services CfDCaPaNCI, editor.2019.

  2. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood. 2006;107(1):265–76. https://doi.org/10.1182/blood-2005-06-2508.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Kridel R, Sehn LH, Gascoyne RD. Pathogenesis of follicular lymphoma. J Clin Invest. 2012;122(10):3424–31. https://doi.org/10.1172/jci63186.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Solal-Céligny P, Bellei M, Marcheselli L, Pesce EA, Pileri S, McLaughlin P, et al. Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. J Clin Oncol. 2012;30(31):3848–53. https://doi.org/10.1200/jco.2010.33.4474.

    Article  PubMed  Google Scholar 

  5. Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015;33(23):2516–22. https://doi.org/10.1200/jco.2014.59.7534.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203–10. https://doi.org/10.1016/s0140-6736(12)61763-2.

    Article  CAS  PubMed  Google Scholar 

  7. Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377(9759):42–51. https://doi.org/10.1016/s0140-6736(10)62175-7.

    Article  CAS  PubMed  Google Scholar 

  8. Maurer MJ, Bachy E, Ghesquières H, Ansell SM, Nowakowski GS, Thompson CA, et al. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. Am J Hematol. 2016;91(11):1096–101. https://doi.org/10.1002/ajh.24492.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Casulo C, Le-Rademacher J, Dixon J, Salles G, Hoster E, Herold M et al. Validation of POD24 as a robust early clinical endpoint of poor survival in follicular lymphoma: results from the follicular lymphoma analysis of surrogacy hypothesis (FLASH) investigation using individual data from 5,453 patients on 13 Clinical Trials. Blood. 2017;130(Supplement 1):412-. doi:https://doi.org/10.1182/blood.V130.Suppl_1.412.412.

  10. Sortais C, Lok A, Tessoulin B, Gastinne T, Mahé B, Dubruille V, et al. Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life. Ann Hematol. 2020;99(7):1595–604. https://doi.org/10.1007/s00277-020-04025-2.

    Article  CAS  PubMed  Google Scholar 

  11. Launonen A, Hiddemann W, Duenzinger U, Fingerle-Rowson G, Nielsen T, Marcus R. Early disease progression predicts poorer survival in patients with follicular lymphoma (FL) in the GALLIUM study. Blood. 2017;130(Supplement 1):1490-. doi:https://doi.org/10.1182/blood.V130.Suppl_1.1490.1490.

  12. John FS, Robert M, Andrew D, Eve G-E, Andrew G, Andrew H, et al. Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. Haematologica. 2019;104(6):1202–8. https://doi.org/10.3324/haematol.2018.209015.

    Article  CAS  Google Scholar 

  13. Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, MacDonald D, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123(19):2944–52. https://doi.org/10.1182/blood-2013-11-531327.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Winter AM, Nastoupil LJ, Becnel MR, Cerhan JR, Habermann TM, Link BK et al. Outcomes of follicular lymphoma patients treated with frontline bendamustine and rituximab: impact of histologic grade and early progression on overall survival. Blood. 2018;132(Supplement 1):4146-. doi:https://doi.org/10.1182/blood-2018-99-118530.

  15. Freeman CL, Kridel R, Moccia AA, Savage KJ, Villa DR, Scott DW, et al. Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma. Blood. 2019;134(9):761–4. https://doi.org/10.1182/blood.2019000258.

    Article  CAS  PubMed  Google Scholar 

  16. Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258–65. https://doi.org/10.1182/blood-2003-12-4434.

    Article  CAS  PubMed  Google Scholar 

  17. Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27(27):4555–62. https://doi.org/10.1200/jco.2008.21.3991.

    Article  PubMed  Google Scholar 

  18. Jurinovic V, Kridel R, Staiger AM, Szczepanowski M, Horn H, Dreyling MH, et al. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood. 2016;128(8):1112–20. https://doi.org/10.1182/blood-2016-05-717355.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W, et al. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood. 2006;108(5):1504–8. https://doi.org/10.1182/blood-2006-01-013367.

    Article  CAS  PubMed  Google Scholar 

  20. Bachy E, Maurer MJ, Habermann TM, Gelas-Dore B, Maucort-Boulch D, Estell JA, et al. A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. Blood. 2018;132(1):49–58. https://doi.org/10.1182/blood-2017-11-816405.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Huet S, Szafer-Glusman E, Xerri L, Bolen C, Punnoose E, Tonon L, et al. Evaluation of clinicogenetic risk models for outcome of follicular lymphoma patients in the PRIMA trial. Hematol Oncol. 2017;35(S2):96–7. https://doi.org/10.1002/hon.2437_85.

    Article  Google Scholar 

  22. Mir F, Mattiello F, Grigg A, Herold M, Hiddemann W, Marcus R, et al. Follicular Lymphoma Evaluation Index (FLEX): a new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy. Am J Hematol. 2020;95(12):1503–10. https://doi.org/10.1002/ajh.25973.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351(21):2159–69. https://doi.org/10.1056/NEJMoa041869.

    Article  CAS  PubMed  Google Scholar 

  24. Huet S, Tesson B, Jais JP, Feldman AL, Magnano L, Thomas E, et al. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. Lancet Oncol. 2018;19(4):549–61. https://doi.org/10.1016/s1470-2045(18)30102-5.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015;16(9):1111–22. https://doi.org/10.1016/s1470-2045(15)00169-2.

    Article  CAS  PubMed  Google Scholar 

  26. Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017;377(14):1331–44. https://doi.org/10.1056/NEJMoa1614598.

    Article  CAS  PubMed  Google Scholar 

  27. Jurinovic V, Passerini V, Oestergaard MZ, Knapp A, Mundt K, Araf S et al. Evaluation of the m7-FLIPI in patients with follicular lymphoma treated within the Gallium trial: EZH2 mutation status may be a predictive marker for differential efficacy of chemotherapy. Blood. 2019;134(Supplement_1):122-. doi:https://doi.org/10.1182/blood-2019-130208.

  28. Lockmer S, Ren W, Brodtkorb M, Østenstad B, Wahlin BE, Pan-Hammarström Q, et al. M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy. Br J Haematol. 2020;188(2):259–67. https://doi.org/10.1111/bjh.16159.

    Article  CAS  PubMed  Google Scholar 

  29. Tobin JWD, Keane C, Gunawardana J, Mollee P, Birch S, Hoang T, et al. Progression of disease within 24 months in follicular lymphoma is associated with reduced intratumoral immune infiltration. J Clin Oncol. 2019;37(34):3300–9. https://doi.org/10.1200/jco.18.02365.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Bachy E, Seymour JF, Feugier P, Offner F, López-Guillermo A, Belada D, et al. Sustained Progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study. J Clin Oncol. 2019;37(31):2815–24. https://doi.org/10.1200/jco.19.01073.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Prochazka VK, Belada D, Janikova A, Benesova K, Mocikova H, Duras J et al. Early follicular lymphoma progression in patients treated with frontline immunochemotherapy with/without rituximab maintenance: clinically meaningful even in chemosensitive individuals. Blood. 2019;134(Supplement_1):3983-. doi:https://doi.org/10.1182/blood-2019-129756.

  32. Seymour JF, Marcus R, Davies A, Gallop-Evans E, Grigg A, Haynes A, et al. Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. Haematologica. 2019;104(6):1202–8. https://doi.org/10.3324/haematol.2018.209015.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Sarkozy C, Trneny M, Xerri L, Wickham N, Feugier P, Leppa S, et al. Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial. J Clin Oncol. 2016;34(22):2575–82. https://doi.org/10.1200/jco.2015.65.7163.

    Article  CAS  PubMed  Google Scholar 

  34. Link BK, Day B-m, Zhou X, Zelenetz AD, Dawson KL, Cerhan JR et al. Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. British Journal of Haematology. 2019;184(4):660–3. doi:https://doi.org/10.1111/bjh.15149.

  35. Jiménez-Ubieto A, Grande C, Caballero D, Yáñez L, Novelli S, Hernández-Garcia MT, et al. Autologous stem cell transplantation for follicular lymphoma: favorable long-term survival irrespective of pretransplantation rituximab exposure. Biol Blood Marrow Transplant. 2017;23(10):1631–40. https://doi.org/10.1016/j.bbmt.2017.05.021.

    Article  PubMed  Google Scholar 

  36. Jiménez-Ubieto A, Grande C, Caballero D, Yáñez L, Novelli S, Hernández-Garcia MT, et al. Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure who reach complete response after rescue treatment. Hematol Oncol. 2018;36(5):765–72. https://doi.org/10.1002/hon.2553.

    Article  PubMed  Google Scholar 

  37. Casulo C, Friedberg JW, Ahn KW, Flowers C, DiGilio A, Smith SM, et al. Autologous transplantation in follicular lymphoma with early therapy failure: a National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. Biol Blood Marrow Transplant. 2018;24(6):1163–71. https://doi.org/10.1016/j.bbmt.2017.12.771.

    Article  PubMed  Google Scholar 

  38. Jurinovic V, Metzner B, Pfreundschuh M, Schmitz N, Wandt H, Peschel C et al. Autologous stem cell transplantation for patients with early progression of follicular lymphoma- retrospective analysis of 2 randomized trials of the German low grade lymphoma study group (GLSG). Blood. 2016;128(22):3464-. doi:https://doi.org/10.1182/blood.V128.22.3464.3464.

  39. Manna M, Lee-Ying R, Davies G, Stewart C, Oh DH, Peters A, et al. Autologous transplantation improves survival rates for follicular lymphoma patients who relapse within two years of chemoimmunotherapy: a multi-center retrospective analysis of consecutively treated patients in the real world. Leuk Lymphoma. 2019;60(1):133–41. https://doi.org/10.1080/10428194.2018.1473576.

    Article  PubMed  Google Scholar 

  40. Smith SM, Godfrey J, Ahn KW, DiGilio A, Ahmed S, Agrawal V, et al. Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. Cancer. 2018;124(12):2541–51. https://doi.org/10.1002/cncr.31374.

    Article  CAS  PubMed  Google Scholar 

  41. Sureda A, Zhang M-J, Dreger P, Carreras J, Fenske T, Finel H, et al. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: a combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. Cancer. 2018;124(8):1733–42. https://doi.org/10.1002/cncr.31264.

    Article  CAS  PubMed  Google Scholar 

  42. Sehn LH, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016;17(8):1081–93. https://doi.org/10.1016/s1470-2045(16)30097-3.

    Article  CAS  PubMed  Google Scholar 

  43. Cheson BD, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, et al. Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study. J Clin Oncol. 2018;36(22):2259–66. https://doi.org/10.1200/jco.2017.76.3656.

    Article  CAS  PubMed  Google Scholar 

  44. Morschhauser F, Le Gouill S, Feugier P, Bailly S, Nicolas-Virelizier E, Bijou F, et al. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study. Lancet Haematol. 2019;6(8):e429–37. https://doi.org/10.1016/s2352-3026(19)30089-4.

    Article  PubMed  Google Scholar 

  45. Andorsky DJ, Coleman M, Yacoub A, Melear JM, Fanning SR, Kolibaba K et al. MAGNIFY: Phase IIIb interim analysis of induction R2 followed by maintenance in relapsed/refractory indolent non-Hodgkin lymphoma. Journal of Clinical Oncology. 2019;37(15_suppl):7513-. doi:https://doi.org/10.1200/JCO.2019.37.15_suppl.7513.

  46. Andorsky DJ, Yacoub A, Melear JM, Coleman M, Kolibaba KS, Brooks HD et al. Phase IIIb randomized study of lenalidomide plus rituximab (R2) followed by maintenance in relapsed/refractory NHL: analysis of patients with double-refractory or early relapsed follicular lymphoma (FL). Journal of Clinical Oncology. 2017;35(15_suppl):7502-. doi:https://doi.org/10.1200/JCO.2017.35.15_suppl.7502.

  47. Andorsky DJ, Coleman M, Yacoub A, Melear JM, Fanning SR, Kolibaba KS et al. MAGNIFY phase IIIb interim analysis of induction R2 followed by maintenance in relapsed/refractory indolent NHL. Journal of Clinical Oncology. 2020;38(15_suppl):8046-. doi:https://doi.org/10.1200/JCO.2020.38.15_suppl.8046.

  48. Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008–18. https://doi.org/10.1056/NEJMoa1314583.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Gopal AK, Kahl BS, Flowers CR, Martin P, Ansell SM, Abella-Dominicis E, et al. Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. Blood. 2017;129(22):3037–9. https://doi.org/10.1182/blood-2016-12-757740.

    Article  CAS  PubMed  Google Scholar 

  50. Dreyling M, Santoro A, Mollica L, Leppä S, Follows GA, Lenz G, et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol. 2017;35(35):3898–905. https://doi.org/10.1200/jco.2017.75.4648.

    Article  CAS  PubMed  Google Scholar 

  51. Dreyling M, Santoro A, Mollica L, Leppä S, Follows GA, Lenz G et al. Long-term efficacy and safety from the copanlisib CHRONOS-1 study in patients with relapsed or refractory indolent B-cell lymphoma. Blood. 2018;132(Supplement 1):1595-. doi:https://doi.org/10.1182/blood-2018-99-114842.

  52. Flinn IW, Patel M, Oki Y, Horwitz S, Foss FF, Allen K, et al. Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study. Am J Hematol. 2018;93(11):1311–7. https://doi.org/10.1002/ajh.25228.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Flinn IW, Miller CB, Ardeshna KM, Tetreault S, Assouline SE, Mayer J, et al. DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma. J Clin Oncol. 2019;37(11):912–22. https://doi.org/10.1200/JCO.18.00915.

    Article  CAS  PubMed  Google Scholar 

  54. TG Therapeutics Announces Positive Results from the UNITY-NHL Phase 2b Pivotal Trial Evaluating Umbralisib Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma [press release]. New York: TG Therapeutics, Inc. https://bit.ly/2JOU8Yn. Accessed 12/2/2020.

  55. Morschhauser F, Tilly H, Chaidos A, McKay P, Phillips T, Assouline S, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 2020;21(11):1433–42. https://doi.org/10.1016/s1470-2045(20)30441-1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Assouline SE, Kim WS, Sehn LH, Schuster SJ, Cheah CY, Nastoupil LJ, et al. Mosunetuzumab Shows promising efficacy in patients with multiply relapsed follicular lymphoma: updated clinical experience from a phase I dose-escalation trial. Blood. 2020;136(Supplement 1):42–4. https://doi.org/10.1182/blood-2020-135839.

    Article  Google Scholar 

  57. Jacobson C, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, et al. Primary analysis of Zuma-5: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). Blood. 2020;136(Supplement 1):40–1. https://doi.org/10.1182/blood-2020-136834.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Contributions

D.W and C.C conceptualized and wrote the work.

Corresponding author

Correspondence to Carla Casulo.

Ethics declarations

Ethics Approval

Not applicable.

Consent to Participate

Not applicable.

Consent for Publication

Not applicable.

Conflict of Interest

D.W reports that they have no conflicts of interest that might be relevant to the contents of this manuscript. C.C reports research funding from Verastem, Gilead, BMS and Genentech/Roche.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Lymphomas

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wallace, D., Casulo, C. Early Progressing Follicular Lymphoma. Curr Oncol Rep 23, 149 (2021). https://doi.org/10.1007/s11912-021-01126-7

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11912-021-01126-7

Keywords

Navigation